Pinax Pharma

Pinax Pharma is a preclinical-stage biotechnology company headquartered in Ann Arbor, Michigan, dedicated to the discovery and development of novel small molecule therapeutics. The company specializes in targeting epigenetic regulators, with a primary focus on the Bromodomain and Extra-Terminal (BET) family of proteins, which play a critical role in gene expression and cancer progression. Pinax Pharma leverages its expertise in medicinal chemistry and structural biology to develop both potent small molecule inhibitors and innovative Proteolysis-Targeting Chimeras (PROTACs) for the treatment of various cancers and inflammatory diseases. Founded by renowned researcher Dr. Shaomeng Wang from the University of Michigan, the company aims to translate cutting-edge academic research into transformative clinical candidates. The company's lead programs are currently in the preclinical stage, focusing on high-potency degraders for hematological malignancies and solid tumors.